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Abstract
Background: The Affordable Medicines Facility - malaria (AMFm) is primarily an artemisinin combination therapy (ACT)
subsidy, aimed at increasing availability, affordability, market share and use of quality-assured ACTs (QAACTs). Mainland
Tanzania was one of eight national scale programmes where AMFm was introduced in 2010. Here we present findings from
outlet and household surveys before and after AMFm implementation to evaluate its impact from both the supply and
demand side.
Methods: Outlet surveys were conducted in 49 randomly selected wards throughout mainland Tanzania in 2010 and 2011,
and data on outlet characteristics and stocking patterns were collected from outlets stocking antimalarials. Household
surveys were conducted in 240 randomly selected enumeration areas in three regions in 2010 and 2012. Questions about
treatment seeking for fever and drugs obtained were asked of individuals reporting fever in the previous two weeks.
Results: The availability of QAACTs increased from 25.5% to 69.5% among all outlet types, with the greatest increase among
pharmacies and drug stores, together termed specialised drug sellers (SDSs), where the median QAACT price fell from $5.63
to $0.94. The market share of QAACTs increased from 26.2% to 42.2%, again with the greatest increase in SDSs. Household
survey results showed a shift in treatment seeking away from the public sector towards SDSs. Overall, there was no change
in the proportion of people with fever obtaining an antimalarial or ACT from baseline to endline. However, when broken
down by treatment source, ACT use increased significantly among clients visiting SDSs.
Discussion: Unchanged ACT use overall, despite increases in QAACT availability, affordability and market share in the
private sector, reflected a shift in treatment seeking towards private providers. The reasons for this shift are unclear, but
likely reflect both persistent stockouts in public facilities, and the increased availability of subsidised ACTs in the private
sector.
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Introduction
The Affordable Medicines Facility- malaria (AMFm) was hailed
as ‘one of the most important recent advances in fighting
malaria’[1], designed to expand access to effective antimalarials
in the public and private sectors[2]. An estimated 3.3 billion
people are at risk of malaria, with 80% of cases in sub-Saharan
Africa[3]. Artemisinin combination therapies (ACTs) are widely
regarded as the best treatment for uncomplicated malaria[3].
However use remains low, reflecting both unreliable public sector
supplies and low availability and high prices of ACTs in the
private sector, which has an increasingly important role in
treatment seeking for malaria[4–6]. These factors lead patients
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to use older, less effective antimalarials such as sulfadoxine-
pyrimethamine (SP) and amodiaquine[4]. There is also concern
about the use of oral artemisinin monotherapies, which may
contribute to the development of artemisinin resistance[7].
The AMFm, an ACT subsidy mechanism, was set up by the
Global Fund to Fight AIDS, Tuberculosis and Malaria to address
some of these barriers to ACT access. AMFm was launched in
2010 as eight national scale programmes in seven countries,
comprising Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania
and Uganda (mainland Tanzania and Zanzibar were considered
as separate pilots). AMFm aimed to increase availability, market
share and use of quality-assured ACTs (QAACTs) while reducing
prices, thereby increasing coverage[8]. This was also intended to
result in ‘crowding out’ of other antimalarials from the market.
AMFm consisted of three main elements: negotiations with
QAACT manufacturers to reduce prices; a copayment made by
the Global Fund to these manufacturers for every purchase made,
representing 80–99% of the factory gate price; and supporting
interventions to increase ACT awareness and appropriate use[9].
AMFm could operate through the public, private for-profit and
private not-for-profit sectors. Eligible importers, termed first line
buyers, placed orders with approved manufacturers. Orders were
then forwarded to the Global Fund AMFm Secretariat for
approval. All copaid QAACTs had a green leaf logo on the
packaging for identification as a subsidised good quality antima-
larial (Figure 1).
Despite these bold aims, AMFm has remained controversial,
with concerns that the reduced price would still present access
barriers for the very poor, that the subsidy would not be
transmitted to the retail level and therefore not benefit the
intended recipients, and that low levels of diagnostic coverage
would lead to poor targeting and overtreatment of parasite
negative individuals[10–12].
Malaria treatment in mainland Tanzania
In Tanzania, about 90% of the population is at risk of
malaria[13]. The Tanzanian government introduced the ACT
artemether-lumefantrine (ALu) to replace SP as the first line drug
for treatment of uncomplicated malaria in 2006, with quinine as
second line treatment. According to national guidelines, ACTs are
provided free at public facilities for under fives, pregnant women,
the elderly and those who cannot afford to pay[14], although these
exemptions are sometimes not fully implemented[15]. Oral
artemisinin monotherapies have been banned since 2008, while
non-oral artemisinin monotherapies are allowed for treatment of
severe disease. ACTs are designated as prescription only medicines
(POMs), while SP is over the counter (OTC). Pharmacies are
allowed to stock POMs, while Duka la Dawa Baridi (DLDB,
meaning ‘drug store’ in Kiswahili) are only allowed to stock OTC
drugs. Since 2006, Tanzania has been in the process of upgrading
DLDBs to Accredited Drug Dispensing Outlets (ADDOs), where
dispensers undergo a 35 day training course and are allowed to
dispense a limited range of POMs including ALu and quinine[16].
A few general stores and kiosks also stock antimalarials, although
this is not permitted.
Diagnosis of fever cases in public health facilities was mainly
based on symptoms alone until the Government changed the
guidelines in 2010 to require parasitological confirmation for
treatment of malaria. Malaria rapid diagnostic tests (mRDTs) were
rolled out in public health facilities in Tanzania between 2010 and
2012[17,18]. Drug retailers are not allowed to stock mRDTs.
AMFm implementation
The AMFm grant agreement between the Global Fund and the
Tanzanian government was signed in August 2010. By December
2011 ten private sector first line buyers were registered in
mainland Tanzania, of which five had placed orders with
manufacturers[19]. The first copaid drugs for the private for-
profit sector arrived in October 2010. By the end of 2011, about 8
million ACT packs had arrived in country for this sector and by
the end of 2012 an additional 16.6 million doses had been
delivered. A maximum recommended retail price (RRP) of 1,000
Tanzanian Shillings (TSh) ($0.64) was set for an adult dose in
private for-profit outlets[9].
The Medical Stores Department was registered as the first line
buyer for the public sector. Public sector orders and deliveries
were delayed, and only started arriving in July 2011. By December
of that year 4.9 million doses had been delivered to the public
sector, and by the end of 2012 a further 4.9 million doses.
Additional public sector supplies were provided by the US
President’s Malaria Initiative, which donated 6.5 million ACT
doses in 2011 and 4.7 million doses in 2012. Despite these
additional supplies, high stockout levels in public health facilities
were reported during AMFm implementation, although these
were similar to stockout levels prior to AMFm[19].
AMFm supporting interventions began in January 2011 in
mainland Tanzania, and included use of national level mass media
and community level communications, to raise awareness of the
copaid drugs, the RRP and the green leaf logo. The mass media
campaign began after the national launch in April 2011, and
included TV and radio adverts and printed material. Community
level communications, including mobile video units, road shows,
clinic shows and school activities were implemented through
community health workers and community based organisations,
and restricted to two districts per region due to budget constraints.
Training was the other major supporting intervention imple-
mented in mainland Tanzania, focusing on the continued
upgrading of drug stores to ADDOs. Upgrading had been
Figure 1. Green leaf logo.
doi:10.1371/journal.pone.0095607.g001
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occurring region by region since 2006. Prior to AMFm
implementation, ADDOs had been introduced in eight of
Tanzania’s then 21 regions. Tanzania had 21 regions at the time
of the study, though this has subsequently been increased to 25. An
additional six regions were covered by the end of 2011, and a
further six by the end of 2012, with progress slower than planned
due to delays in disbursements from the Global Fund. In addition,
a one day re-training programme covering malaria, Integrated
Management of Childhood Illness and family planning was
implemented in ADDOs in two regions in August to September
2011. Other smaller scale supporting interventions comprised
strengthening of pharmacovigilance and monitoring and evalua-
tion activities.
This paper explores the impact of AMFm from both the supply
and demand sides, specifically assessing changes between baseline
and endline (pre and post AMFm implementation) in the following
five areas:
- Availability of QAACTs
- Price of QAACTs
- Market share of QAACTs
- Choice of provider for treatment of fever
- ACT use
Supply side data are drawn from outlet surveys conducted in
2010 and 2011 in all regions of mainland Tanzania as part of the
multi-country Independent Evaluation of AMFm[19]. Demand
side data are drawn from household surveys conducted in 2010
and 2012 in three regions of Tanzania with varying malaria
transmission (Mwanza, Mbeya and Mtwara), as part of the
IMPACT2 project (www.actconsortium.org/IMPACT2).
Methods
The study had a non-experimental, before and after design. As
AMFm was implemented nationally there were no comparison
areas.
Outlet surveys were conducted using methods adapted from the
ACTwatch project[20]. Baseline outlet survey data collection took
place from September to November 2010, and endline data
collection from October 2011 to January 2012. 49 wards were
randomly selected at baseline and endline, respectively, with
probability proportional to population size, stratified by urban/
rural location. One ward had to be dropped at baseline so data
from 48 wards was analysed. Wards were designated as urban or
rural using National Bureau of Statistics Census classifications,
with mixed wards classified as urban if more than 70% of the ward
was classified as urban. In each selected ward, every outlet with the
potential to sell antimalarials was visited, including public and
private health facilities, pharmacies, ADDOs, drug stores, general
stores, kiosks and community health workers. Outlets were
identified using official lists from district and national authorities,
by consulting with district pharmacists and other local leaders, and
by driving or walking down every street within a ward to locate all
outlets. In large wards with a population over 30,000 people,
wards were segmented, and one or more segments of the ward
were randomly selected for the survey. As pharmacies were
relatively rare but thought to be a major source of treatment, they
were oversampled, whereby all pharmacies in the district in which
the selected ward was located were visited.
The sample size was calculated to detect a 20 percentage point
change in outlets stocking a QAACT between baseline and
endline, in urban and rural domains, with 80% power, 5%
significance and at baseline assumed a design effect of 4 and 40%
availability of QAACTs. Using these criteria, 305 outlets which
stocked antimalarials were required in both urban and rural
domains at baseline and endline. Estimates of the average
numbers of outlets per ward were used to estimate the number
of wards required to reach this number of outlets: 9 urban and 39
rural at baseline. This was then adjusted at endline to 20 urban
and 29 rural wards, reflecting baseline estimates of availability and
the higher degree of clustering observed at baseline in urban areas.
Screening criteria were used to identify outlets with an
antimalarial in stock at the time of visit or within the previous
three months. Following verbal consent, a questionnaire was
conducted with the most senior staff member present, in Kiswahili,
with data collected using Personal Digital Assistants (PDAs).
Questions about outlet characteristics were asked, and details
about every antimalarial in stock at the time of visit were recorded,
as well as the volumes of each product sold in the past seven days.
Antimalarials were classified as quality-assured ACTs
(QAACTs), non-quality-assured ACTs, artemisinin monotherapies
(broken down by oral and non-oral forms), or non-artemisinin
therapies such as SP, chloroquine, mefloquine and amodiaquine.
QAACTs are ACTs that comply with the Global Fund’s quality
assurance policy[21]. Price and market share data were calculated
using Adult Equivalent Treatment Doses (AETDs), the amount of
a drug needed to completely treat a 60 kg adult[22]. For example,
to calculate the price per AETD of a paediatric package of ALu
with 6 standard tablets (20 mg artemether and 120 mg lumefan-
trine), the price would be multiplied by 4 to calculate what it
would cost for an adult equivalent dose of 24 tablets.
The household surveys took place in Mwanza, Mbeya and
Mtwara regions, which have varying malaria transmission and
epidemiology. Baseline household data collection took place from
June to October 2010, and endline from May to September 2012.
Mwanza is located next to Lake Victoria, Mtwara is in the south
on the coast, and Mbeya is located in the southern highlands. In
2011–2012 malaria prevalence among children aged 6–59 months
was 18.6% in Mwanza, 17.4% in Mtwara and 0.5% in
Mbeya[23]. Based on the national distribution of socio-economic
status, Mbeya had the lowest percentage of people living in the
lowest wealth quintile of the three regions, at 7.7%, compared to
20.8% in Mwanza and 35.5% in Mtwara [24]. mRDT roll out in
public facilities took place in all three regions between the baseline
and endline household surveys, in early 2011 in Mwanza and
Mbeya, and in mid-2012 in Mtwara. The ADDO programme had
been implemented in Mbeya and Mtwara regions by baseline, and
was implemented in Mwanza region after endline household data
collection.
In each region, 80 enumeration areas (EAs) were randomly
selected using probability proportional to population size. In
selected EAs, every household was visited and mapped using
Global Positioning System. After obtaining a list of all the
households within an EA, 32 households were randomly selected
while in the field, 24 to be visited first, and the remaining eight to
be included sequentially as replacements if any of the initial 24
households were unavailable or refused to be interviewed. At
baseline, the maximum number of households visited per
enumeration area was 32 in Mwanza, and 24 in Mbeya and
Mtwara. At endline the maximum was 24 in all regions. The
sample size was calculated to detect a 10 percentage point increase
in children under five with a febrile illness who obtained ACT
within 24 hours of fever onset. With 80% power, 5% significance
and an assumed design effect of two, 480 children under five with
fever were required in each region.
The questionnaire was translated into Kiswahili, and data were
collected using PDAs. Questions on household demographics were
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asked of the household head, and questions on history of fever
were asked of all household members. All members who reported
fever in the 14 days prior to interview were asked about treatment
sought and drugs and blood tests obtained. The guardian was
interviewed on behalf of children below 12 years old. In addition,
a finger prick blood sample was taken from all consenting
members, from which an mRDT was performed (ICT Diagnos-
tics, Cape Town, South Africa). Written consent was obtained
from everybody who was interviewed or had blood taken, or from
their guardian.
Data analysis for the outlet and household surveys was
performed using Stata version 11 (College Station, Texas). Stata
survey procedures were used to account for the survey design and
stratification. Changes in availability and use were assessed using
the design based F-test. R version 2.14.2 was used in outlet survey
analysis for obtaining p-values for the change in retail prices using
the Wilcoxon Rank Sum test. 2011 and 2012 prices were
converted to 2010 prices using the Tanzania consumer price
index. Prices were converted to US dollars using the average
interbank rate for 2010. Socio-economic status quintiles were
calculated using principal components analysis, based on the first
principal component, and using standard Demographic and
Health Survey variables[24].
In addition, key informant interviews were conducted at
national, regional and district level to capture information on
the process of AMFm implementation and relevant contextual
factors[19]. Interviewees were drawn from government bodies
such as the National Malaria Control Programme and the
Tanzania Food and Drug Authority, non-governmental organisa-
tions such as the Clinton Health Access Initiative, organisations
implementing supporting interventions, as well as regional and
district medical officers and other local staff. We draw on the
information gathered to inform the Discussion section of this
paper.
Ethical approval was obtained from the Institutional Review
Board of Ifakara Health Institute and the London School of
Hygiene and Tropical Medicine Research Ethics Committee for
both the outlet and household surveys, including collection of
blood samples during the household survey, and also from the
Institutional Review Board of ICF International for the outlet
survey. The investigator from the US Centers for Disease Control
and Prevention provided technical assistance for the household
survey but was not actively engaged in data collection for either
survey.
Results
Antimalarial availability, price and market share
Of all outlets visited, 709 met the screening criteria at baseline
and 799 at endline (Table 1). 93.0% and 99.9% of outlets that met
the screening criteria were interviewed at baseline and endline
respectively.
Outlets were classified as: public health facilities (dispensaries,
health centres and hospitals); private health facilities (for-profit and
not-for-profit dispensaries, clinics and hospitals); specialised drug
sellers (SDSs) (pharmacies and drug stores, including DLDB and
ADDOs); and general retailers (general stores and kiosks). Private
not-for-profit and private-for-profit health facilities were pooled
due to low numbers obtained. Only one community health worker
stocked an antimalarial at baseline and none at endline, so results
for this subgroup are not presented separately but are included in
total estimates.
In total, 15.8% and 14.0% of outlets visited stocked an
antimalarial at baseline and endline, respectively (p = 0.31).
Antimalarial availability was over 80% at baseline and endline
in public health facilities, private health facilities and SDSs, while
general retailers had the lowest availability of 4.3% at baseline and
0.9% at endline (p = 0.024) Of outlets stocking antimalarials, the
percentage with at least one staff member with a health related
qualification was above 98% in public and private health facilities
at both baseline and endline, and increased from 89.7% to 97.1%
in SDSs (p = 0.002).
Availability of QAACTs. Availability of specific antimalarial
categories was calculated out of outlets stocking any antimalarials.
QAACT availability increased from 25.5% among all outlets at
baseline to 69.5% at endline (p,0.001) (Figure 2). This was mainly
due to the substantial increase in SDSs, where availability
increased from 12.8% to 69.6% (p,0.001). Availability in general
retailers increased from 4.3% to 20.6% (p,0.001). No change was
seen in QAACT availability in public health facilities, which was
80.1% at baseline and 81.4% at endline (p = 0.86). A decrease in
the availability of non-artemisinin therapies in public health
facilities led to a small but significant decrease overall (98.4% to
94.8%, p= 0.020). There was a small increase in availability of
non-quality-assured ACTs (14.2% to 25.3%, p= 0.046), which was
not significant in any one outlet type. The first line drug ALu
accounted for 94.8% of QAACTs and 4.7% of non-quality-
assured ACTs found in stock at baseline, and 94.4% of QAACTs
and 9.0% of non-quality-assured ACTs at endline.
Price of QAACTs. The median price of QAACTs was zero
in public and private facilities as they were supposed to be
provided free in all public and most private not-for-profit facilities.
Median price data for SDSs are shown in Table 2, for tablets only
to enhance comparability across antimalarial types as QAACTs
are only available in tablet form. The median price of QAACT
tablets in SDSs fell from $5.63 to $0.94 (p,0.001). Non-
artemisinin therapy tablets had a median price in SDSs below
$1 at baseline and endline, and at endline the median price of
QAACT tablets was equal to that of non-artemisinin therapy
tablets. The median price of non-quality-assured ACT tablets also
decreased in SDSs from $7.92 to $6.87 (p= 0.025) though the
magnitude of the decrease was not as great as that for QAACTs.
Market share of QAACTs. The market share of QAACTs
as a percentage of all reported antimalarial sales increased from
26.2% to 42.2% among all outlet types combined (p= 0.033)
(Figure 3), with a particularly large increase in SDSs from 2.2% to
34.0% (p,0.001). No significant changes were seen in QAACT
market share in public or private health facilities. The market
share of non-quality-assured ACTs did not change significantly
and the market share of artemisinin monotherapies was minimal,
below 1.0% in all outlet types at baseline and endline. Therefore
the increased QAACT market share was at the expense of non-
artemisinin therapies, for which the market share decreased by 13
percentage points among all outlet types combined.
Urban/rural variation in availability, price and market
share. When broken down by urban and rural areas, large
increases were seen in QAACT availability in both urban and
rural areas overall, and especially in SDSs (Annex S1). At baseline,
there was higher availability of QAACTs in urban SDSs than rural
SDSs (p= 0.028), but at endline there was no significant difference
between the areas. Decreases in median QAACT prices were seen
in both urban and rural areas, although greater reductions were
seen in urban areas as there were few QAACTs in rural areas at
baseline and the majority of these were very inexpensive (Annex
S2). The increase in QAACT market share was almost completely
due to changes in rural areas, where market share increased by
25.4 percentage points, compared with 1.8 percentage points in
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urban areas (Annex S3). However, significant increases were seen
in market share in SDSs in both urban and rural areas.
Treatment sought and obtained for malaria
5,423 and 5,511 households were interviewed at baseline and
endline, respectively, involving 20,874 and 20,102 full interviews
of household members or their guardian (Table 3). Over four fifths
of household heads worked in agriculture, and about half had
completed primary school. Overall parasite prevalence among all
age groups according to study mRDT results was 17.5% at
baseline and 12.0% at endline (p,0.001).
Choice of provider for treatment of fever. Overall 69.5%
of people with fever sought care at baseline and 73.6% at endline
(p = 0.074), with seeking care defined to include care sought
outside the home and drugs obtained from home/a neighbour.
Only 3.8% of people with fever at baseline and 2.7% at endline
sought care in more than one place.
There was a marked shift from baseline to endline away from
public health facilities and general retailers and towards SDSs
overall and in each age group, with an increase from 41.3% to
54.1% in people visiting SDSs (p,0.001) and a decrease from
25.3% to 16.8% in people visiting a public health facility (p,
0.001) as the first source of care overall (Figure 4). The change in
use of SDSs and public health facilities was considerable in both
age groups, with the increase in SDS use being highest among
under fives, from 28.6% to 48.3% (p,0.001).
ACT use. Overall the percentage of people with fever who
obtained an antimalarial was 40.6% at baseline and 35.9% at
endline (p = 0.070), and did not change to an important degree in
either age group (Figure 5a). The percentage of people with fever
who obtained an ACT was 20.7% at both baseline and endline
(p = 1.00). There was weak evidence for an increase in the
percentage of people who obtained an ACT, out of those who
obtained an antimalarial between baseline (51.0%) and endline
(57.7%) (p = 0.077), corresponding with the slight fall in all people
with a febrile illness getting an antimalarial and no change in those
getting an ACT.
Other marked changes were seen in these three core household
indicators when broken down by where the patient sought care.
Figure 5b shows the data separately for visits to public health
facilities and SDSs, the two sources where the majority of people
sought care. In public health facilities the percentage of people
obtaining an ACT decreased from 57.4% to 46.1% (p= 0.035),
but there were no marked differences in the percentage of people
obtaining an antimalarial, or an ACT out of those obtaining an
antimalarial. The percentage of people visiting SDSs obtaining an
antimalarial decreased from 60.5% to 51.0% (p= 0.026), while the
proportion obtaining an ACT increased from 18.5% to 26.9% in
these outlets (p = 0.015). The percentage obtaining an ACT out of
those who obtained an antimalarial increased from 30.6% to
52.7% in SDSs (p,0.001). When broken down by socio-economic
status there was no substantial changes in any of the three use
indicators in any quintile (Figure 6).
Use of diagnostic tests. The percentage of people obtaining
a blood test was 17.6% at baseline and 21.4% at endline overall
(p = 0.78), with no major change in any age group. In public
health facilities the percentage of people who obtained a blood test
increased from 28.7% to 46.6% (p,0.001), while in SDSs there
was weak evidence of a decrease (4.1% to 2.1%, p= 0.061)
Table 1. Description of outlet survey sample at baseline and endline.
Baseline
Number
enumerated
Number
screened
Number which
met screening
criteria*
Number
interviewed
Number with
antimalarials in stock
at time of visit
Number of
antimalarials
audited
Public Health
Facilities
76 72 70 64 61 232
Private Health
Facilities
40 40 35 34 33 191
Specialised Drug
Sellers
545 524 502 467 463 5,020
General Retailers 2,484 2,478 199 92 72 90
Community Health
Workers
5 5 2 2 1 3
Total 3,150 3,119 709 659 630 5,536
Endline
Public Health
Facilities
62 59 59 59 55 244
Private Health
Facilities
37 34 32 32 32 275
Specialised Drug
Sellers
743 687 684 684 683 9,132
General Retailers 2,936 2,921 24 23 17 40
Community Health
Workers
1 1 0 0 0 0
Total 3,779 3,702 799 798 787 9,691
*An outlet met the screening criteria if there was an antimalarial in stock at the time of visit or within the previous three months.
Source: Outlet surveys in 2010 and 2011.
doi:10.1371/journal.pone.0095607.t001
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Price paid for ACTs. Households were also asked about the
price they had paid for antimalarials. The median price paid for
ALu tablets from SDSs at baseline was $1.41 (interquartile range
(IQR) $0.85 to $1.88) per AETD, and at endline was $1.29 (IQR
$0.86 to $2.15). At endline, the median price of ALu with the
green leaf logo from SDSs was $1.08 (IQR $0.81 to $2.15) and
Figure 2. Of all outlets stocking antimalarials, percentage stocking (a) quality-assured ACTs, (b) non-quality-assured ACTs, (c)
artemisinin monotherapies, and (d) non-artemisinin therapies, by outlet type at baseline and endline. * denotes p,0.05 for change
over time Error bars denote 95% confidence intervals HFs: Health facilities Source: Outlet surveys in 2010 and 2011.
doi:10.1371/journal.pone.0095607.g002
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without the logo was $1.29 (IQR $1.08 to $2.15). At baseline 68%
of ACTs from public health facilities were reported to have been
obtained for free and 63% at endline (p = 0.53). Of drugs not
obtained for free, the median cost was $0.70 at baseline and $1.08
at endline in this sector.
Regional and urban/rural variation in provider choice
and ACT use. Somewhat different treatment seeking patterns
were seen in rural and urban areas and across the three regions
visited (Annex S4–S6). In rural areas and in Mbeya and Mtwara
regions a shift away from public health facilities towards SDSs
occurred, but in Mwanza and in urban areas this was not
significant, reflecting the high usage of SDSs at baseline. The
proportion of people with febrile illness who obtained an
antimalarial decreased significantly in Mtwara, and in rural areas,
while the proportion of people obtaining ACT and the proportion
obtaining ACT out of those obtaining an antimalarial did not
change to a substantial degree in any setting.
Discussion
This paper has presented results from large scale baseline and
endline outlet and household surveys to explore the impact of
AMFm from both a supply and demand perspective. The paper
demonstrates how very different inferences can be drawn from
looking at each side of the market, and therefore the importance of
a holistic approach to evaluation.
Table 2. Median retail price per Adult Equivalent Treatment Dose of antimalarial drugs in tablet form in specialised drug sellers at
baseline and endline (2010 USD).
Baseline Endline
N Median price [IQR] N Median price [IQR]
Quality-assured ACTs 277 5.63 [1.70–8.45] 1,795 0.94 [0.62–1.25]*
Non-quality-assured ACTs 1,130 7.92 [5.99–13.52] 1,781 6.87 [3.75–12.96]
Non-artemisinin therapies 1,960 0.85 [0.63–1.27] 2,719 0.94 [0.63–1.25]
IQR: Inter quartile range.
*denotes p,0.05 for change over time using Wilcoxon rank sum test.
Artemisinin monotherapies not presented due to low numbers obtained.
Source: Outlet surveys in 2010 and 2011.
doi:10.1371/journal.pone.0095607.t002
Figure 3. Market share by antimalarial category: percent distribution of antimalarial sales volumes by antimalarial category at
baseline and endline. HFs: Health facilities *denotes p,0.05 for change over time Source: Outlet surveys in 2010 and 2011.
doi:10.1371/journal.pone.0095607.g003
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Before discussing the results further it should be noted that the
surveys had several limitations. They were both based on reported
data from providers and community members, and therefore
potentially subject to recall bias. In addition, outlet staff may have
biased their answers to make them more socially desirable or due
to fear of regulatory consequences. For example, they may have
concealed certain POMs, including ACTs, if they were concerned
that their outlet was not authorised to sell them, especially at
baseline before ACTs were widely promoted in the private sector.
In addition, they may have stated lower retail prices than they
actually charge, especially at endline when the RRP was widely
publicised. Similarly, in the household survey, respondents may
have overstated their use of ACTs if they knew this was the
‘correct’ answer, or stated that they went to a public health facility
instead of another source.
Another factor to consider is the different timings and
geographical coverage of the surveys. The outlet surveys were
conducted between September 2010 and January 2012, in all
regions of mainland Tanzania, while the household surveys were
conducted between June 2010 and September 2012, in three
regions only. The endline outlet survey was conducted relatively
early on during AMFm implementation: twelve months after
subsidised drugs first arrived and five months after the commu-
nication campaigns commenced, while the household survey was
conducted nine months later. It is unclear whether a longer time
period before endline would be associated with greater impact as
the programme became more established, or less impact as the
effect of initial training and communications waned.
Finally, the evaluation was based on a before and after study
design. Lack of control areas means that it is challenging to assess
what would have happened in the absence of AMFm and to what
extent the changes seen are attributable to the programme. Below
we draw on findings from key informant interviewers to address
these issues where possible.
Key informants indicated that there were no major delays in
obtaining copaid drugs by private sector buyers and the supply
chain from manufacturer to buyers generally operated smoothly,
after an initial slow start in early 2011. The outlet surveys showed
that in the private sector QAACT availability and market share
increased while retail price decreased after AMFm implementa-
tion, with the household surveys showing large improvements in
ACT use among SDS customers. In these outlets, although the
proportion of people getting an antimalarial decreased, those
obtaining an ACT increased, resulting in a substantial increase in
the proportion of people getting an ACT out of those getting an
antimalarial. Key informants did not identify any other projects or
contextual issues that could have been responsible for changes of
this scale in the retail sector, implying that they were very likely
due to AMFm.
Table 3. Description of household survey sample at baseline and endline.
Baseline Endline
Description of households (HHs):
HHs mapped 31,600 39,864
HHs selected 6,177 6,051
HHs that participated 5,423 5,511
Description of household members: Age group Age group
,5 $5 Total ,5 $5 Total
HH members registered 26,924 25,407
HH members interviewed 4,143 16,731 20,874 4,063 16,034 20,102
Percentage interviewed who were male 49.1 41.3 42.9 49.6 41.5 43.2
HH members with study mRDT results* 3,986 15,940 19,926 3,732 14,384 18,116
Percentage parasite positive by study mRDT 15.9 17.8 17.5 11.7 12.1 12.0
Socio-demographic characteristics of households:
Occupation of household head: % (95% CI) % (95% CI)
Agriculture 82.1 (77.9–85.7) 82.6 (79.1–85.6)
Unskilled manual labour 4.4 (3.2–6.0) 3.7 (2.9–4.8)
Skilled manual labour 2.9 (2.1–3.9) 2.2 (1.7–2.8)
Domestic service 1.7 (1.0–2.8) 1.4 (1.0–2.0)
Sales and services 5.7 (4.3–7.8) 5.9 (4.4–7.8)
Clerical 0.2 (0.0–0.6) 0.0 (0.0–0.3)
Professional/technical/managerial 3.0 (0.2–3.8) 4.2 (3.1–5.7)
Education status of household head:
None 26.0 (23.9–28.2) 28.5 (26.4–30.7)
Primary Incomplete 15.8 (14.5–17.2) 15.4 (13.9–16.9)
Completed Primary 51.9 (49.7–54.1) 50.0 (48.0–52.1)
Completed 4 years of secondary or higher 6.3 (4.9–8.0) 6.1 (4.8–7.7)
*Malaria Rapid Diagnostic Test results not obtained due to people not consenting to the test, leaving before the test was conducted or unreadable results.
Source: Household surveys in 2010 and 2012.
doi:10.1371/journal.pone.0095607.t003
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By contrast, outlet survey data showed no significant change
was seen in QAACT availability or market share in the public
sector. Household survey data showed that the proportion of
people obtaining an ACT at public facilities actually fell. This
likely partly reflected the persistence of ACT stockouts in public
facilities, and the significant increase in blood tests between
baseline and endline due to mRDT roll out. Health facility surveys
in the same three regions in 2010 and 2012 also reported a
significant decrease in the percentage of people with fever
obtaining ACTs from 39.9% to 21.3%, along with an increase
in the percentage of people obtaining a blood test from 15.9% to
55.8%[18].
Key informants reported that the supply chain in this sector
proved more problematic than that for the private sector, with
severe delays in procuring and obtaining copaid drugs through
AMFm channels. The 4.9 million doses of copaid QAACTs
delivered by the end of 2011 were estimated to be only two to four
months worth of supplies, and the extra doses donated by the US
President’s Malaria Initiative were still insufficient to prevent
stockouts due to the low stock levels before AMFm, leading to
similar QAACT availability in public health facilities at baseline
and endline. These delays in receiving public sector copaid drugs
were said to have been partly caused by delays in ordering due to
the confusion over the new grant mechanisms, delays in approvals
being granted, and delays in delivery owing to manufacturers’
inability to meet the high global demand for drugs at the time.
Despite the improvements seen on the supply side in the private
sector, household survey data showed that the overall proportion
of people obtaining an ACT during a febrile illness had not
changed, with only one fifth of patients obtaining an ACT before
and after AMFm implementation. There are two possible
explanations for this apparent paradox. First, while ACT use
increased in the private sector, there was a reduction in the
proportion of public sector patients obtaining ACT, reflecting
increased use of mRDTs, as described above. Secondly, the
proportion of people obtaining an ACT remained higher in the
public sector than the private sector at endline, so the shift in
treatment seeking towards the private sector therefore also had a
negative effect on the overall proportion of people getting ACTs.
These two effects therefore cancelled out the increase in ACT use
in the private sector. To clarify further, at baseline, 25% of visits
for fever/malaria treatment were to the public sector, of which
57% resulted in an ACT being obtained, compared to 41% and
19% respectively in SDSs; at endline 17% of visits were to the
public sector and 46% of these obtained an ACT, while this was
54% and 27% respectively in SDSs. The result was that at
baseline, of people with fever, 14% visited a public health facility
and obtained an ACT, while 8% visited an SDS and obtained an
ACT; at endline, 8% of people visited a public health facility and
obtained an ACT, and 15% visited an SDS and obtained an ACT.
Overall, the proportion of people who visited a public health
facility or drug store and obtained an ACT therefore remained
unchanged at 22%.
Figure 4. Choice of first provider for treatment of fever in the past two weeks by age group at baseline and endline. * denotes p,0.05
for change over time **Other includes seeking treatment from home, a neighbour or a traditional healer Source: Household surveys in 2010 and 2012.
doi:10.1371/journal.pone.0095607.g004
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The market share of QAACTs overall increased significantly
while the use of ACTs did not change, which could be affected by
certain factors such as the different timings and geographical areas
of the outlet and household surveys. At baseline the QAACT
market share could potentially have been underreported which
would have resulted in an overestimate of the change in market
share.
The observed shift in treatment seeking behaviour may have
reflected a number of factors. Qualitative data collected as part of
the IMPACT2 project indicated that community members were
very aware of public sector drug stockouts, and as a result tended
to bypass public facilities and seek treatment elsewhere[25].
Coupled with an increasingly abundant supply of good quality,
affordable medicines in the retail sector due to AMFm this could
have encouraged people to make the private sector their first
source of care. A continuation of the ongoing general expansion of
the private health sector over time could also have played a part,
although the shift seen over one year is likely too large to be
attributed to this trend alone. The upgrading of DLDB to ADDOs
might also be expected to increase the number of outlets selling
POMs and therefore ACTs, encouraging more people to use the
private sector. However, the shift in treatment seeking was seen in
both ADDO and non-ADDO regions, and DLDB were also
known to widely stock POMs illegally.
Figure 5. Percentage of people who reported fever in the past two weeks who obtained any antimalarial and an ACT at baseline
and endline by (a) age in years, and (b) source of care. SDSs: Specialised Drug Sellers; Public HFs: Public health facilities * denotes p,0.05 for
change over time; Error bars denote 95% confidence intervals Source: Household surveys in 2010 and 2012.
doi:10.1371/journal.pone.0095607.g005
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Household survey data showed no change in the price paid for
ALu tablets, as the prices paid at baseline were very low, and
much cheaper than the QAACT prices reported in the outlet
survey at baseline. A possible explanation for this is that some ALu
tablets in SDSs at baseline may have been leaked from public
health facilities, and sold very cheaply to household members, but
concealed from interviewers during the baseline outlet survey. It is
also likely that relatively costly ALu tablets available in the private
sector at baseline were too expensive for most community
members, and therefore rarely purchased or recorded in the
household survey.
A study in relatively remote areas of two Tanzanian regions in
2011–12 showed similar outlet survey results, with availability of
AMFm subsidised ACTs increasing from 25% to 88% in ADDOs
in Mtwara, and from 3% to 62% in Rukwa between February
2011 and January 2012 [26]. This was accompanied by a decrease
in median price from $1.03 to $0.81. However, household surveys
in the same region found a significant increase in ACT use among
suspected malaria cases from 54.6% to 67.8%, mainly reflecting
increased ACT use in the retail sector[27]. A shift in treatment
seeking towards the retail sector was seen, but in contrast to our
findings, this reflected a shift from those not seeking care rather
than from the public sector. However, results from the Tanzania
HIV/AIDS and Malaria Indicator Surveys in 2010 and 2012 were
consistent with our study findings, showing no change in the
proportion of children under five who obtained an ACT out of all
those with fever, or out of those who obtained an antimalarial
[23].
In comparison with the other seven AMFm pilots, mainland
Tanzania was fairly successful in terms of outlet survey outcomes
[9], with the third highest increase in QAACT availability, and the
third largest fall in median QAACT price, but only the sixth
highest increase in overall QAACT market share.
Baseline and endline household survey data were available for
four of the other seven AMFm pilots. Similar to mainland
Tanzania, results from Zanzibar also showed large improvements
Figure 6: Treatment obtained for fever in the past two weeks by socio-economic status. * denotes p,0.05 for change over time Error bars
denote 95% confidence intervals Source: Household surveys in 2010 and 2012.
doi:10.1371/journal.pone.0095607.g006
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in QAACT availability, affordability and market share in the
private for-profit sector but no change in overall ACT use[28]. As
above, this likely reflected a reduction in the relative importance of
the public sector as a source of antimalarials, with the share of all
antimalarials distributed through the public sector falling from
37% at baseline to 13% at endline[19]. However, these
contrasting household and outlet survey results were not found
in Uganda, Nigeria or Madagascar. Uganda experienced a large
and significant increase in ACT use in under fives (24.0 percentage
points)[28], despite weaker performance on outlet survey out-
comes. Nigeria and Madagascar saw smaller increases in ACT use
of 6.7 and 5.0 percentage points respectively. Household survey
data were not available for Kenya and Ghana, which experienced
the strongest results for outlet survey indicators.
The Global Fund has decided to integrate AMFm into core
Global Fund grant management, after a transition period in
2013[29]. This means that eligible countries will be able to use
their core Global Fund resources to buy copaid drugs under the
AMFm system, but this use of grant funds for ACT subsidies will
compete with all other interventions for malaria, HIV/AIDS and
tuberculosis. The Tanzanian government has committed to
continuing with ACT subsidies, though concerns have been raised
about poor targeting of copaid ACTs to those with malaria in the
private sector. For example, Briggs et al. showed that after AMFm
implementation in Mwanza and Mtwara, only 20% of people
purchasing ACTs from DLDBs or ADDOs were parasitaemic[30].
Strategies to increase diagnostic use in the private sector have
received considerable attention in national and international
policy discussions[31], with some stakeholders keen to build on
experience from Cambodia where subsidised mRDTs have been
distributed through the private sector for over a decade[32]. The
Tanzanian government is currently piloting the introduction of
low cost and subsidised mRDTs in ADDOs, with the intention of
improving targeting of subsidised ACTs to those with confirmed
parasitaemia.
This research has highlighted that other key policy consider-
ations should include how to combine improved access to quality,
affordable ACTs in the private sector while maintaining use of the
public sector, particularly through improvements in public sector
ACT availability. Ultimately the goal should be to have affordable,
high quality testing and treatment available in both the public and
private sectors.
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